Brain HealthAlzheimer's Research Reaches Turning Point With New Therapies and Biomarkers
Alzheimer's disease (AD) remains the world's leading cause of dementia, and a sweeping new review in Cell synthesizes the most important recent advances in understanding and treating it. Beyond the well-known amyloid plaques and tau tangles, researchers now recognize a far more complex web of pathologies driving neurodegeneration. Encouragingly, new disease-modifying therapies can now meaningfully slow cognitive decline by clearing amyloid from the brain — a genuine milestone. The review spotlights breakthroughs in APOE biology, the brain's immune system, and blood-based biomarkers that are transforming how AD is detected and staged. While a cure remains out of reach, the science is accelerating rapidly, and the authors argue that a future where AD is both treatable and preventable is coming into focus.
